

REGULATORY CIRCULAR #RG99-177

September 8, 1999

TO: Members and Member Organizations

ATTENTION: Chief Executive Officers/Managing Partners/
Compliance Officers/Senior Registered Options Principals

FROM: Capital Markets Division

SUBJECT: TARGETS TRUST IV

The following Securities are the subject of a Preliminary Prospectus and will commence trading on a date to be announced (Ticker Symbol: TAE; CUSIP: 87612X104).

Targeted Growth Enhanced Term Securities ("TARGETS")
With Respect to the Common Stock of Amgen Inc.
Due on __, 2002

Holders of TARGETS will receive cash distributions of per quarter on each and , beginning , 1999. At maturity, Holders are entitled to an amount equal to the product of (i) the then Current Market Price** of Amgen common stock as of the Maturity Date multiplied by (ii) the "Exchange Rate". The Exchange Rate shall be 0.125 if the Market Price** of the Common Stock on the Maturity Date is less than or equal to an Appreciation Cap*. If the Market Price is greater than the Appreciation Cap*, then the Exchange Rate shall be a fraction -- the numerator being the Appreciation Cap times 0.125 and the denominator being the Market Price of Amgen common stock as of the Maturity Date.

TARGETS represent preferred undivided beneficial ownership interests in the assets of TARGETS Trust IV, a recently formed business trust ("Trust"). The Trust exists for the sole purpose of issuing TAE and will invest approximately 85-90% of the proceeds of the offering to purchase from Salomon Smith Barney, a forward contract with respect to the common stock of Amgen Inc., and approximately 10-15% of the proceeds from the offer will be used to purchase certain Treasury Securities.

The purpose of this circular is to provide basic information to Members and Member Organizations regarding a proposed new issue of Equity Linked Notes based upon Amgen common stock and to advise of certain compliance responsibilities when handling transactions in these securities. This is not a sales document and is not intended to be distributed to customers.

* To be announced

** As more fully described in the Prospectus, the "Current Market Price" will generally be based on the average price of Amgen common stock, for the 10 days prior to, but not including, one business day before the maturity date.

CERTAIN RISK FACTORS

- TAE differs from most types of trust preferred securities in that the payment that a Holder will receive at maturity is not fixed, but rather will be based on the average Market Price of Amgen Common Stock during the 10 days prior to maturity. There can be no assurance that the amount of such payment will be equal to or greater than the amount an investor initially paid for the TARGETS. Therefore, purchasers of TAE bear the full risk of a decline in the value of Amgen common stock prior to maturity of TAE.
- The opportunity for equity appreciation afforded by an investment in TAE is less than the opportunity for appreciation afforded by a direct investment in Amgen common stock. As a result of the Appreciation Cap*, Holders of TAE will only be entitled to a maximum of * of any appreciation in the value of Amgen common stock.
- The market price of TAE at any time will be affected primarily by changes in the price of Amgen common stock and by complex and interrelated political, economic, financial and other factors that can affect the capital markets.
- Although the yield on TAE may be higher than the yield on Amgen common stock, there can be no assurance that any difference will remain throughout the life of the instrument.
- Upon the occurrence of an Acceleration Event (as set forth in the Prospectus), the maturity date will be accelerated and the Trustee will sell the Treasury Securities, liquidate the Trust and cause the Accelerated Maturity Payment with respect to each TARGETS and a pro rata portion of the Treasury Proceeds to be distributed to Holders of the TARGETS.

OTHER IMPORTANT INFORMATION:

- Investors should consider the tax consequences of investing in TARGETS. See “United States Federal Income Tax Considerations” in the Prospectus.
- The Securities are backed only by Salomon Smith Barney Holdings Inc.
- Amgen is not in any way involved with this offering and has no obligation with respect to these securities.
- Holders of TAE will not be entitled to any rights with respect to Amgen common stock including, without limitation, voting rights, and dividends or other distributions.
- TAE will be quoted and traded in round lots of 100, and will trade “flat” without accrued interest.

The foregoing information has been excerpted from the Preliminary Prospectus, and the Exchange assumes no responsibility for the accuracy or completeness of such information. Members and associated persons of member organizations are advised to read both the Preliminary Prospectus and the final Prospectus.

REGULATORY CONSIDERATIONS

MARGIN AND CAPITAL REQUIREMENTS

For margin and capital purposes, TAE will be considered an equity security. A long TAE position will have an initial and maintenance margin requirement equal to 50% and 25% of market value, respectively.

TAE does not qualify as an options hedge under the Securities and Exchange Commission's Rule 15c3-1 (the "Net Capital Rule") or the Exchange's margin rules. Therefore, members should be aware that making markets in or trading TAE, or any structured product that does not qualify as an options hedge, will subject the Member to the provisions of the Net Capital Rule. Members should refer to Regulatory Circular RG 97-40 for further information regarding capital requirements and structured products.

For capital purposes, TAE positions will be subject to a haircut equal to 15% of market value. Currently, there are no haircut offsets for related derivative securities. It should be noted, however, that CBOE believes that this may soon change, as the SEC is reviewing a proposal to allow haircut offsets for related derivatives with regard to equity linked products in general and for TAE in particular. Further information will be forthcoming as it becomes available.

SALES PRACTICES

TAE is considered an equity security and is subject to the provisions of Rule 30.50. A customer's account is not required to be options approved. Members and associated persons of Member Organizations should take such steps as may be reasonably necessary to assure that prospective purchasers of TAE reach an investment decision only after carefully considering the suitability of the security in light of their particular financial circumstances and objectives.

Members and Member Organizations should not recommend purchases or sales in TAE unless they have reason to believe that the recommended transaction is not unsuitable for such customer in light of the customer's financial circumstances and objectives.

SEC Rule 10a-1 ("short sales") applies to TAE as do "front running" prohibitions.

* * *

Questions regarding suitability of customers transactions in these securities should be directed to Barry Szurgot (312) 786-7756 and questions regarding marginability should be directed to Jim Adams (312) 786-7718. General product questions should be directed to Nick Parcharidis of the Capital Markets Division (212) 803-1411.

